Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42,252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Tam CS, et al. Among authors: yu y. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24. Blood. 2019. PMID: 31340982 Free PMC article. Clinical Trial.
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
An G, Zhou D, Cheng S, Zhou K, Li J, Zhou J, Xie L, Jin J, Zhong L, Yan L, Guo H, Du C, Zhong J, Yu Y, Wu B, Qiu L. An G, et al. Among authors: yu y. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. doi: 10.1158/1078-0432.CCR-21-0539. Epub 2021 Jul 12. Clin Cancer Res. 2021. PMID: 34253577 Free PMC article. Clinical Trial.
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.
Song Y, Sun M, Qi J, Xu W, Zhou J, Li D, Li J, Qiu L, Du C, Guo H, Huang J, Tang Z, Ou Y, Wu B, Yu Y, Zhu J. Song Y, et al. Among authors: yu y. Br J Haematol. 2022 Jul;198(1):62-72. doi: 10.1111/bjh.18162. Epub 2022 Apr 5. Br J Haematol. 2022. PMID: 35383885 Free PMC article. Clinical Trial.
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
Xu W, Yang S, Zhou K, Pan L, Li Z, Gao S, Zhou D, Hu J, Feng R, Huang H, Wang T, Li D, Ji M, Guo H, Zhao X, Wu B, Yu Y, Wang Y, Huang J, Novotny W, Li J. Xu W, et al. Among authors: yu y. Leuk Lymphoma. 2023 Mar;64(3):712-716. doi: 10.1080/10428194.2022.2164692. Epub 2023 Feb 17. Leuk Lymphoma. 2023. PMID: 36799536 Free article. No abstract available.
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, García-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyż J, Fernández De Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Wu B, Yu Y, Shen Z, Chan WY, Schneider J, Allewelt H, Cohen A, Dimopoulos MA. Tam CS, et al. Among authors: yu y. Blood Adv. 2024 Apr 9;8(7):1639-1650. doi: 10.1182/bloodadvances.2023010906. Blood Adv. 2024. PMID: 38315878 Free PMC article.
[Analysis of perinatal factors for death or severe intraventricular hemorrhage within the first week of life in preterm infants with gestational age <32 weeks].
Wang LR, Liu XL, Yang CH, Yu YH, Liu J; Sino-northern Neonatal Network Collaborative Group. Wang LR, et al. Among authors: yu yh. Zhonghua Er Ke Za Zhi. 2025 Mar 17;63(4):387-393. doi: 10.3760/cma.j.cn112140-20241219-00926. Online ahead of print. Zhonghua Er Ke Za Zhi. 2025. PMID: 40090916 Chinese.
Naturally inspired chimeric quinolone derivatives to reverse bacterial drug resistance.
Wen Q, He Y, Chi J, Wang L, Ren Y, Niu X, Yang Y, Chen K, Zhu Q, Lin J, Xiang Y, Xie J, Chen W, Yu Y, Wang B, Wang B, Zhang Y, Lu C, Wang K, Teng P, Zhou R. Wen Q, et al. Among authors: yu y. Eur J Med Chem. 2025 Mar 12;289:117496. doi: 10.1016/j.ejmech.2025.117496. Online ahead of print. Eur J Med Chem. 2025. PMID: 40088661
Impact of Frailty in Patients With Continuous-Flow Left Ventricular Assist Device Therapy in End-Stage Heart Failure: A Systematic Review and Meta-Analysis.
Costa C, Arjomandi Rad A, Yu YT, Mayooran N, Xanthopoulos A, Koulouroudias M, Vardanyan R, Guida GA, Wilkinson L, Schmitto J, Ruhparwar A, Zubarevich A, Weymann A, Sardari Nia P, Kourliouros A, Athanasiou T. Costa C, et al. Artif Organs. 2025 Mar 14. doi: 10.1111/aor.14998. Online ahead of print. Artif Organs. 2025. PMID: 40087871 Review.
Measurement of Very-High-Energy Diffuse Gamma-Ray Emissions from the Galactic Plane with LHAASO-WCDA.
Cao Z, Aharonian F, Axikegu, Bai YX, Bao YW, Bastieri D, Bi XJ, Bi YJ, Bian W, Bukevich AV, Cao Q, Cao WY, Cao Z, Chang J, Chang JF, Chen AM, Chen ES, Chen HX, Chen L, Chen L, Chen L, Chen MJ, Chen ML, Chen QH, Chen S, Chen SH, Chen SZ, Chen TL, Chen Y, Cheng N, Cheng YD, Chu MC, Cui MY, Cui SW, Cui XH, Cui YD, Dai BZ, Dai HL, Dai ZG, Danzengluobu, Dong XQ, Duan KK, Fan JH, Fan YZ, Fang J, Fang JH, Fang K, Feng CF, Feng H, Feng L, Feng SH, Feng XT, Feng Y, Feng YL, Gabici S, Gao B, Gao CD, Gao Q, Gao W, Gao WK, Ge MM, Ge TT, Geng LS, Giacinti G, Gong GH, Gou QB, Gu MH, Guo FL, Guo J, Guo XL, Guo YQ, Guo YY, Han YA, Hannuksela OA, Hasan M, He HH, He HN, He JY, He Y, Hor YK, Hou BW, Hou C, Hou X, Hu HB, Hu Q, Hu SC, Huang C, Huang DH, Huang TQ, Huang WJ, Huang XT, Huang XY, Huang Y, Huang YY, Ji XL, Jia HY, Jia K, Jiang HB, Jiang K, Jiang XW, Jiang ZJ, Jin M, Kang MM, Karpikov I, Khangulyan D, Kuleshov D, Kurinov K, Li BB, Li CM, Li C, Li C, Li D, Li F, Li HB, Li HC, Li J, Li J, Li K, Li SD, Li WL, Li WL, Li XR, Li X, Li YZ, Li Z, Li Z, Liang EW, Liang YF, Lin SJ, Liu B, Liu C, Liu D, Liu DB, Liu H, Liu HD, Liu J, Liu JL, Liu MY, Liu RY, Liu SM, Liu W, Liu Y, Liu YN, Luo Q, Luo Y, L… See abstract for full author list ➔ Cao Z, et al. Among authors: yu yh. Phys Rev Lett. 2025 Feb 28;134(8):081002. doi: 10.1103/PhysRevLett.134.081002. Phys Rev Lett. 2025. PMID: 40085904
Drupacine as a potent SARS-CoV-2 replication inhibitor in vitro.
Yang C, Yu Y, Peng Q, Song J, Sun B, Shi Y, Ding Q. Yang C, et al. Among authors: yu y. Biosaf Health. 2024 Sep 3;6(5):270-278. doi: 10.1016/j.bsheal.2024.09.001. eCollection 2024 Oct. Biosaf Health. 2024. PMID: 40078736 Free PMC article.
TGFβ-activated Asporin interacts with STMN1 to promote prostate cancer docetaxel chemoresistance and metastasis by upregulating the Wnt/β-catenin signaling pathway.
Ge S, Cen J, Liu X, Hong Y, Tang Y, Yu Y, Li H, Xie T, Wang C, Cai M, Qiu Y, Zeng X, Peng T, Li Q, Li Q, Wu X, Song XL, Zhao SC. Ge S, et al. Among authors: yu y. Drug Resist Updat. 2025 Mar 8;81:101227. doi: 10.1016/j.drup.2025.101227. Online ahead of print. Drug Resist Updat. 2025. PMID: 40073743
Placental targeted drug delivery: a review of recent progress.
Wang L, Mu Q, Zhang W, Zheng W, Zhu X, Yu Y, Wang Y, Xu W, Lu Z, Han X. Wang L, et al. Among authors: yu y. Nanoscale. 2025 Mar 12. doi: 10.1039/d4nr05338a. Online ahead of print. Nanoscale. 2025. PMID: 40070242 Review.
Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study.
Yu Y, Li Y, Cui R, Yan Y, Li F, Chen Y, Wang T, Hu X, Feng Y, Yu T, Huang Y, Sun J, Lyu R, Xiong W, Wang Q, Liu W, An G, Sui W, Xu Y, Huang W, Zou D, Wang H, Xiao Z, Wang J, Qiu L, Yi S. Yu Y, et al. Among authors: yu t. Signal Transduct Target Ther. 2025 Mar 12;10(1):85. doi: 10.1038/s41392-025-02164-4. Signal Transduct Target Ther. 2025. PMID: 40069155 Free PMC article. Clinical Trial.
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.
Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, Huser N, Yuan JT, Cianfrogna JA, Sung T, McMillan E, Wei N, Carmody J, Kang AN, Darensburg S, Dodd T, Oakley JV, Solowiej J, Nguyen L, Orr STM, Chen P, Johnson E, Yu X, Diehl WC, Gallego GM, Jalaie M, Ferre RA, Cho-Schultz S, Shen H, Deal JG, Zhang Q, Baffi TR, Xu M, Roh W, Lapira-Miller J, Goudeau J, Yu Y, Gupta R, Kim K, Dann SG, Kan Z, Kath JC, Nair SK, Miller N, Murray BW, Nager AR, Quinlan C, Petroski MD, Zhang C, Sacaan A, VanArsdale T, Anders L. Palmer CL, et al. Among authors: yu x, yu y. Cancer Cell. 2025 Mar 10;43(3):464-481.e14. doi: 10.1016/j.ccell.2025.02.006. Cancer Cell. 2025. PMID: 40068598
Investigation of the Blood Microbiome in Horses With Fever of Unknown Origin.
Sun Y, Yu YT, Castillo XO, Anderson R, Wang M, Sun Q, Tallmadge R, Sams K, Reboul G, Zehr J, Brown J, Wang X, Marra N, Stanhope B, Grenier J, Pusterla N, Divers T, Mittel L, Goodman LB. Sun Y, et al. Among authors: yu yt. Vet Med Sci. 2025 Mar;11(2):e70272. doi: 10.1002/vms3.70272. Vet Med Sci. 2025. PMID: 40065594 Free PMC article.
Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: a Phase 4, multi-centre, open-label study.
Yuan J, Guo F, Li A, Xu N, Chang X, Xiao Z, Zeng H, Qiao H, Tang L, Yu Y, Liu B, Wang P, Irani P, Pypstra R, Lu J, Liu F, Mu Y, Huang H, Zhang Y. Yuan J, et al. Among authors: yu y. J Glob Antimicrob Resist. 2025 Mar 8:S2213-7165(25)00061-X. doi: 10.1016/j.jgar.2025.03.001. Online ahead of print. J Glob Antimicrob Resist. 2025. PMID: 40064443
42,252 results
You have reached the last available page of results. Please see the User Guide for more information.